1-3 of 3
Eugenia Haralambieva
Close
Sort by
Journal Articles

A patient with a germline GATA2 mutation and primary myelofibrosis

Clinical Trials & Observations
Cyrill V. Rütsche, Eugenia Haralambieva, Veronika Lysenko, Stefan Balabanov, Alexandre P. A. Theocharides
Journal: Blood Advances
Blood Adv (2021) 5 (3): 791–795.
https://doi.org/10.1182/bloodadvances.2020003401
Published: 2021
Includes: Supplemental data
Journal Articles

BRAF V 600E or mutant MAP2K1 human CD34 + cells establish Langerhans cell–like histiocytosis in immune-deficient mice

Anahita Rafiei, C. Matthias Wilk, Patrick M. Helbling, Renier Myburgh, Yasuyuki Saito, Eugenia Haralambieva, Davide Soldini, Rikhia Chakraborty, Miriam Merad, Carl E. Allen, Cesar Nombela-Arrieta, Markus G. Manz
Journal: Blood Advances
Blood Adv (2020) 4 (19): 4912–4917.
https://doi.org/10.1182/bloodadvances.2020001926
Published: 2020
Includes: Supplemental data
Journal Articles

Lymphadenopathy driven by TCR-V γ 8V δ 1 T-cell expansion in FAS-related autoimmune lymphoproliferative syndrome

Clinical Trials & Observations
Stefano Vavassori, Jacob D. Galson, Johannes Trück, Anke van den Berg, Rienk Y. J. Tamminga, Aude Magerus-Chatinet, Olivier Pellé, Ulrike Camenisch Gross, Ewerton Marques Maggio, Seraina Prader, Lennart Opitz, Ursina Nüesch, Andrea Mauracher, Benjamin Volkmer, Oliver Speer, Luzia Suda, Benno Röthlisberger, Dieter Robert Zimmermann, Rouven Müller, Arjan Diepstra, Lydia Visser, Eugenia Haralambieva, Bénédicte Neven, Frédéric Rieux-Laucat, Jana Pachlopnik Schmid
Journal: Blood Advances
Blood Adv (2017) 1 (15): 1101–1106.
https://doi.org/10.1182/bloodadvances.2017006411
Published: 2017
Includes: Supplemental data